Spero Therapeutics Inc (NASDAQ:SPRO) does about 3.69M shares in volume on a normal day but saw 2539688 shares change hands in the recent trading day. The company now has a market cap of 139.78M USD. Its current market price is $2.50, marking a decrease of -2.34% compared to the previous close of $2.56. The 52 week high reached by this stock is $2.95 whilst the lowest price level in 52 weeks is $0.51.
The consensus objective for the share price is $5.00, suggesting that the stock has a potential upside of 50.0% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Hold the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 20, 2024 when Evercore ISI downgraded the stock to “In-line” and issued a price target of $5. Evercore ISI upgraded the stock to “Outperform” from In-line on September 23, 2022 at a price target of $2-$8.
The current price level is 78.04%, 159.14%, and 136.53% away from its SMA20, SMA50, and SMA200 respectively, with the SPRO price moving below the 50-day SMA on current market day. Its price is 142.72% year-to-date and 74.83% over the past year.
To reach the target analysts have set, the stock logically needs to grow 50.0 percent from here.
Outstanding shares total 55.90M with insiders holding 24.32% of the shares and institutional holders owning 23.25% of the company’s common stock. The company has a return on investment of -193.90% and return on equity of -107.28%. The beta has a value of 1.31. Price to book ratio is 4.13 and price to sales ratio is 4.94.
